Defibrotide sodium
Based on 1 Customer Validation
Defibrotide sodium is a complex mixture of single stranded polydeoxyribonucleotides. Defibrotide sodium has liver protection, anti-inflammatory, antithrombotic, profibrinolytic, and anti-ischemic properties. Defibrotide sodium can be used for sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 90.00%
- CAS. Nr.: 83712-60-1
- Molecular Weight:13-20 (KDa)
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Defibrotide sodium’s anti-inflammatory effects occur via agonism at adenosine A1 and A2 receptors, which reduces expression of intracellular adhesion molecule-1 and inhibits release of inflammatory mediators[1].
Defibrotide sodium inhibits platelet aggregation by enhancing production of prostaglandins I2 and E2 and stimulates fibrinolysis via increasing tPA activity and inhibiting plasminogen activator inhibitor type 1 activity[1].
Defibrotide sodium also decreases production of tissue factor and increases production of tissue factor pathway inhibitor, resulting in decreased activation of the extrinsic coagulation cascade and fibrin deposition[1].
Defibrotide sodium protects against endothelial cell damage mediated by tumor necrosis factor α and fludarabine-induced activation and apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Intravenous (i.v.) administration of thrombin (20 μg/kg) in rabbits induces a reversible accumulation of radiolabelled platelets into the thoracic circulation which is significantly reduced by i.v. administration of defibrotide (64 mg/kg bolus plus 64 mg/kg/h for 1 h) prior to i.v. thrombin[2].
Intravenous injection of human thrombin (1250 μg/kg) to mice induces death within the majority of animals which is significantly reduced by pretreatment with defibrotide (150-175 mg/kg, i.v.)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 83712-60-1
-
Appearance Liquid
-
Molecular Weight 13-20 (KDa)
-
Color Colorless to light yellow
-
SMILES
[Defibrotide (sodium)]
-
Versand
Shipping with dry ice.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2242 KB)
Verweise
[1]. May T Aziz, et al. Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome. Ann Pharmacother. 2018 Feb;52(2):166-174. [Content Brief]
[2]. W Paul, et al. The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits. Br J Pharmacol. 1993 Dec;110(4):1565-71. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Defibrotide sodium Related Classifications
HY-108746 Related Classifications
Powered by Bioz